Skylar Jeremias

December 23, 2022

Here are the top 5 biosimilar articles for the week of December 19, 2022.

December 22, 2022

Ian Henshaw, senior vice president and global head of biosimilars at Biogen, describes the importance of awareness campaigns like the International Generic and Biosimilar Medicines Association's Global Biosimilars Week and how these initiatives can be leveraged to improve biosimilar adoption and acceptance.

December 21, 2022

Over 2 years after a cabinet vote to establish a biosimilar switching policy, the Ontario government is putting one in place, making it the seventh province and eighth jurisdiction in Canada to do so.

December 19, 2022

Janssen filed a lawsuit against Amgen, claiming the latter infringed on the former’s patents when creating its ustekinumab biosimilar, and Express Scripts announced that it would add adalimumab biosimilars to formulary.

December 18, 2022

On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.

December 16, 2022

Here are the top 5 biosimilar articles for the week of December 12, 2022.

December 15, 2022

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, tackles how stakeholders can collaborate and utilize market data to effectively boost biosimilar uptake.

December 14, 2022

Fresenius Kabi announced the FDA approval of its adalimumab biosimilar Idacio (adalimumab-aacf), making it the eighth biosimilar referencing Humira (adalimumab) to be approved in the United States.

December 12, 2022

The FDA has accepted Biogen’s biologics license application for a tocilizumab biosimilar candidate (BIIB800) referencing Actemra for review.

December 11, 2022

John Gabrielson, senior vice president at JSR Life Sciences and head of Similis Bio, shares how the recent codevelopment deal between Similis and Blau Farmaceutica differs from commercialization and licensing deals many other companies have signed with each other.